Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering HS donors in COVID-19 therapy
British Journal of Pharmacology, ISSN: 1476-5381, Vol: 177, Issue: 21, Page: 4931-4941
2020
- 73Citations
- 98Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations73
- Citation Indexes73
- 73
- CrossRef55
- Captures98
- Readers98
- 98
Review Description
The COVID-19 pandemic caused by SARS-Cov-2 demands rapid, safe and effective therapeutic options. In the last decades, the endogenous gasotransmitter hydrogen sulfide (HS) has emerged as modulator of several biological functions and its deficiency has been associated with different disorders. Therefore, many HS-releasing agents have been developed as potential therapeutic tools for diseases related with impaired HS production and/or activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of HS in modulating the inflammatory response and pro-inflammatory cytokine cascade is well recognized, and the usefulness of some HS-donors for the treatment of acute lung inflammation has been reported. Recent data is elucidating several mechanisms of action, which may account for antiviral effects of HS. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous HS levels and severity of COVID-19. Therefore, repurposing of HS-releasing drugs may be a potential therapeutic opportunity for treatment of COVID-19. Linked Articles: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
Bibliographic Details
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know